MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516839-27-00

Acronym

MITO 35a

Enrollment

200

Registered

2024-12-09

Start date

2024-12-09

Completion date

Unknown

Last updated

2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

Brief summary

PFS number of subjects who are progression- free from the beginning of the first line treatment

Detailed description

1) PFS 2 Progression Free Survival 2 2) OS Overall Survival 3) toxicity profile (CTCAE 5.0 version) every 4 weeks (28gg) 4) Define if there are prognostic factors between the biological and clinical characteristics of patients and tumor biomarkers, which can identify patients who have a better prognosis in terms of OS

Interventions

DRUGLynparza 150 mg film-coated tablets

DRUGLynparza 100 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS number of subjects who are progression- free from the beginning of the first line treatment	—

Secondary

Measure	Time frame
1) PFS 2 Progression Free Survival 2 2) OS Overall Survival 3) toxicity profile (CTCAE 5.0 version) every 4 weeks (28gg) 4) Define if there are prognostic factors between the biological and clinical characteristics of patients and tumor biomarkers, which can identify patients who have a better prognosis in terms of OS	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026